From Auto- to Allotransplantation: Immunomodulatory Protocol for Hand and Arm Transplantation

Journal of Reconstructive Microsurgery
W P Andrew LeeGerald Brandacher

Abstract

To achieve a favorable risk-benefit balance for hand transplantation, an immunomodulatory protocol was developed in the laboratory and translated to clinical application. Following donor bone marrow infusion into transplant recipients, hand and arm allografts have been maintained on low-dose tacrolimus monotherapy. Good-to-excellent functional recovery has been achieved in patients compliant with medication and therapy, thus restoring autonomous and productive lives. The risk-benefit balance can be tilted in favor of the hand transplant recipients by using an immunomodulatory protocol with minimum immunosuppression.

Citations

May 29, 2019·Plastic and Reconstructive Surgery·Carrie A KubiakPaul S Cederna
May 23, 2020·Plastic and Reconstructive Surgery. Global Open·Kun Hwang, Se Jin Hwang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.